A/Prof Alex Swarbrick

Laboratory Head - Tumour Progression Lab

A/Prof Alex Swarbrick

Alex graduated with a Bsc (Hons I) in Molecular and Cellular Biology from UNSW in 1995. After obtaining his PhD in 2003 he undertook postdoctoral training with Nobel laureate J. Michael Bishop at the University of California, San Francisco, supported by a CJ Martin Travelling Fellowship from the NHM

Research Level

Principal Research Fellow

Biography

Alex graduated with a Bsc (Hons I) in Molecular and Cellular Biology from UNSW in 1995. After obtaining his PhD in 2003 he undertook postdoctoral training with Nobel laureate J. Michael Bishop at the University of California, San Francisco, supported by a CJ Martin Travelling Fellowship from the NHMRC.

In 2008 Alex established the Tumour Progression Laboratory in the Garvan Institute and in 2012 was appointed co-Head of the Breast Translational Oncology Program in the newly commissioned Kinghorn Cancer Centre. Alex is an Associate Professor at UNSW and an NHMRC Senior Research Fellow. He is the Petre Foundation Chair of Breast Cancer Research.

Alex is the immediate-past convenor of the Lorne Cancer Conference, Australia's pre-eminent multi-disciplinary cancer research conference & the Australian Translational Breast & Prostate Cancer Symposium. He serves on the Cancer Research Committee of the Cancer Council NSW.

Alex graduated with a Bsc (Hons I) in Molecular and Cellular Biology from UNSW in 1995. After obtaining his PhD in 2003 he undertook postdoctoral training with Nobel laureate J. Michael Bishop at the University of California, San Francisco, supported by a CJ Martin Travelling Fellowship from the NHMRC.

In 2008 Alex established the Tumour Progression Laboratory in the Garvan Institute and in 2012 was appointed co-Head of the Breast Translational Oncology Program in the newly commissioned Kinghorn Cancer Centre. Alex is an Associate Professor at UNSW and an NHMRC Senior Research Fellow. He is the Petre Foundation Chair of Breast Cancer Research.

Alex is the immediate-past convenor of the Lorne Cancer Conference, Australia's pre-eminent multi-disciplinary cancer research conference & the Australian Translational Breast & Prostate Cancer Symposium. He serves on the Cancer Research Committee of the Cancer Council NSW.

Awards and Honours

2020- Petre Chair of Breast Cancer Research
2019- National Health and Medical Research Council Senior Research Fellowship
2013 - National Health and Medical Research Council Career Development Fellowship II
2012 - National Breast Cancer Foundation Fellowship
2011 - NSW Premier’s Award for Outstanding Research Fellow 2011
2009 - CINSW Early Career Fellowship
2007 - Sydney University Medal for Excellence in Medical Research

Education

2003 - PhD, University of New South Wales, Sydney - Australia
1995 - Molecular Biology, 1st Class Honours, University of New South Wales, Sydney - Australia

Patents

Australian Provisional Patent Application

Methods of treating breast cancer and reagents therefore

 

Australian Provisional Patent Application

Methods of treating neuroblastoma and reagents therefore

 

Australian Provisional Patent Application 2018903546 

 Phenotypic and molecular characterisation of single cells

 

 

Selected Publications

 

Wu, S. Z., D. Roden, al., E. Lim, S. X. Liu and A. Swarbrick "Stromal cell diversity associated with immune evasion in human triple-negative breast cancer" EMBO Journal In Press

Baker, L.A., H. Holliday, D. Roden, C. Krisp, S.Z. Wu, S. Junankar, . . . A. Swarbrick, Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer. Breast Cancer Res, 2020. 22(1): p. 63.

Owen, K.L., L.J. Gearing, D.J. Zanker, N.K. Brockwell, W.H. Khoo, D.L. Roden, . . . B.S. Parker, Prostate cancer cell-intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone. EMBO Rep, 2020. 21(6): p. e50162.

Piggin, C. L., D. L. Roden, A. M. K. Law, M. P. Molloy, C. Krisp, A. Swarbrick, M. J. Naylor, M. Kalyuga, W. Kaplan, S. R. Oakes, D. Gallego-Ortega, S. J. Clark, J. S. Carroll, N. Bartonicek and C. J. Ormandy (2020). "ELF5 modulates the estrogen receptor cistrome in breast cancer." PLoS Genet 16(1): e1008531.

Singh, M., G. Al-Eryani, S. Carswell, J. M. Ferguson, J. Blackburn, K. Barton, D. Roden, F. Luciani, T. Giang Phan, S. Junankar, K. Jackson, C. C. Goodnow, M. A. Smith and A. Swarbrick (2019). "High-throughput targeted long-read single cell sequencing reveals the clonal and transcriptional landscape of lymphocytes." Nat Commun10(1): 3120.

Cazet, A. S., M. N. Hui, B. L. Elsworth, S. Z. Wu, D. Roden, C. L. Chan, J. N. Skhinas, R. Collot, J. Yang, K. Harvey, M. Z. Johan, C. Cooper, R. Nair, D. Herrmann, A. McFarland, N. Deng, M. Ruiz-Borrego, F. Rojo, J. M. Trigo, S. Bezares, R. Caballero, E. Lim, P. Timpson, S. O'Toole, D. N. Watkins, T. R. Cox, M. S. Samuel, M. Martin and A. Swarbrick (2018). "Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer." Nature Communications 9(1): 2897.

Lin, H. M., I. Nikolic, J. Yang, L. Castillo, N. Deng, C. L. Chan, N. K. Yeung, E. Dodson, B. Elsworth, C. Spielman, B. Y. Lee, Z. Boyer, K. J. Simpson, R. J. Daly, L. G. Horvath and A. Swarbrick (2018). "MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer." Sci Rep 8(1): 7820.

Lin, H. M., K. L. Mahon, C. Spielman, H. Gurney, G. Mallesara, M. R. Stockler, P. Bastick, K. Briscoe, G. Marx, A. Swarbrick and L. G. Horvath (2017). "Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer." Br J Cancer 116(8): 1002-1011.

Nikolic, I., B. Elsworth, E. Dodson, S. Z. Wu, C. M. Gould, P. Mestdagh, G. M. Marshall, L. G. Horvath, K. J. Simpson and A. Swarbrick (2017). "Discovering cancer vulnerabilities using high-throughput micro-RNA screening." Nucleic Acids Research 45(22): 12657-12670.

Beckers, R. K., C. Selinger, R. Vilain, J. Madore, J. S. Wilmott, K. Harvey, A. Holliday, C. L. Cooper, E. Robbins, D. Gillet, C. W. Kennedy, L. Gluch, H. Carmalt, C. Mak, S. Warrier, H. E. Gee, C. Chan, A. McLean, E. Walker, C. M. McNeil, J. M. Beith, A. Swarbrick, R. A. Scolyer and S. A. O'Toole (2016). "PDl1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome." Pathology 48 Suppl 1: S146-S147.

Junankar, S., B. L., D. L. Roden, R. Nair, B. Elsworth, D. Gallego-Ortega, P. Lacaze, A. Cazet, I. Nikolic, W. Siang-Teo, J. Yang, A. McFarland, K. Harvey, M. J. Naylor, S. R. Lakhani, P. T. Simpson, A. Raghavendra, J. Saunus, J. Madore, W. Kaplan, C. Ormandy, E. K. A. Millar, S. O'Toole, K. Yun and A. Swarbrick (2015). "ID4 controls mammary stem cells and marks breast cancers with a stem cell-like phenotype " Nature Communications6: 6548.

Junankar, S., G. Shay, J. Jurczyluk, N. Ali, J. Down, N. Pocock, A. Parker, A. Nguyen, S. Sun, B. Kashemirov, C. E. McKenna, P. I. Croucher, A. Swarbrick, K. Weilbaecher, T. G. Phan and M. J. Rogers (2015). "Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer." Cancer Discovery 5(1): 35-42.

Phua, Y. W., A. Nguyen, D. Roden, B. Elsworth, N. Deng, I. Nikolic, J. Yang, A. McFarland, R. Russell, W. Kaplan, M. Cowley, R. Nair, E. Zotenko, S. O'Toole, S. X. Tan, D. E. James, S. J. Clark, H. Kouros-Mehr and A. Swarbrick (2015). "MicroRNA profiling of the pubertal mouse mammary gland identifies miR-184 as a candidate breast tumour suppressor gene." Breast Cancer Res 17(1): 83.

O'Toole SA, Machalek DA, Shearer RF, Millar EK, Nair R, Schofield P, McLeod D, Coooper CL, McNeil CM, McFarland A, Nguyen A, Ormandy CJ, Qiu MR, Rabinovich B, Martelotto LG, Vu D, Hanningan GE, Musgrove EA, Christ D, Sutherland RL, Watkins DN, Swarbrick A. Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. Cancer Research, 71:4002-4014 (2011).

Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A, Chanthery Y, Lim L, Ashton LJ, Judson RL, Huskey N, Blelloch R, Haber M, Norris MD, Lengyel P, Hackett CS, Preiss T, Chetcuti A, Sullivan CS, Marcusson EG, Weiss W, L'Etoile N, Goga A. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat Medicine, 16:1134-1140, doi:10.1038/nm.2227 (2010).